TPI 1100 is a inhaled inhibitor against phosphodiesterases (PDEs), PDE 4 and PDE 7. PDEs are a group of enzymes that are validated targets for chronic obstructive pulmonary disease (COPD).
Topigen has also reprioritized its pipeline candidates for COPD and is expected to fund for further development of TPI 1100 after determining that it is a more promising candidate for COPD than TPI 1020. This follows the results of a Phase II study that was recently completed for TPI 1020 in patients with COPD, which showed good safety and tolerability, but did not demonstrate the desired activity profile.
TPI 1020 is an anti-inflammatory respiratory drug licensed from NicOx for respiratory indications. Potential opportunities for TPI 1020 in other indications are currently being explored by NicOx and Topigen under an ongoing collaboration agreement.
Mark Parry-Billings, CEO of Topigen, said: PDE inhibition is a very exciting area with great potential in fighting inflammatory respiratory diseases. With regulatory approval to evaluate TPI 1100 in the clinic, we look forward to moving this product candidate through development.
Our decision to not invest further in TPI 1020 for COPD reflects the systematic approach Topigen will continue to take in focusing resources on the development programs with the greatest chance of achieving clear differentiation and value in the respiratory market.